MedTrace Logo

Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma

NCT03998033 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2022-08-23

No results posted yet for this study

Summary

This is a open-label, dose escalation, multi-center, Phase I / Phase II study to assess the safety of an autologous T-cell product (ET140202) in adult subjects with advanced Alpha-fetoprotein (AFP) positive/Human Leukocyte Antigen (HLA) A-2 positive Hepatocellular Carcinoma (HCC).

Conditions

Interventions

BIOLOGICAL

ET140202 autologous T cell product

Autologous T cells transduced with lentivirus encoding an ET140202 expression construct

Sponsors & Collaborators

  • Eureka Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Eureka Study Director · Eureka Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-30
Primary Completion
2020-12-31
Completion
2020-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03998033 on ClinicalTrials.gov